BIIB

Biogen Inc. (NASDAQ:BIIB) is a pioneering biotechnology company founded in 1978 and headquartered in Cambridge, Massachusetts. Originally established as one of the first biotechnology companies focused on developing treatments for neurological diseases, Biogen has evolved from a multiple sclerosis specialist into a diversified biopharmaceutical company. The company went public in 1991 and has since become a leading developer of therapies for neurological, neurodegenerative, and rare diseases. Over the past few years, Biogen has undergone a strategic transformation, transitioning from its traditional focus on multiple sclerosis treatments to a broader portfolio that includes breakthrough therapies for Alzheimer's disease, rare neurological conditions, and immunological disorders.